A blog from the Centre for Research Ethics & Bioethics (CRB)

Tag: antimicrobial resistance

Can consumers contribute to more responsible antibiotic use?

Most people are probably aware that antimicrobial resistance is one of the major threats to global health. When microorganisms develop resistance to antibiotics, more people become seriously ill from common infections and more people will die from them. It is like an arms race. By using antibiotics to defend ourselves against infections, we speed up the development of resistance. Since we need to be able to defend ourselves against infections, antibiotics must be used more responsibly so that the development of resistance is slowed down.

However, few of us are equally aware that food production also contributes significantly to the development of antimicrobial resistance. In animal husbandry around the world, large amounts of antibiotics are used to defend animals against infections. The development of resistance is accelerated to a large extent here, when the microorganisms that survive the antibiotics multiply and spread. In addition, antibiotics from animal husbandry can leek out and further accelerate the development of antimicrobial resistance in an antibiotic-contaminated environment. Greater responsibility is therefore required, not least in the food sector, for better animal husbandry with reduced antibiotic use.

Unfortunately, the actors involved do not seem to feel accountable for the accelerated development of antimicrobial resistance. There are so many actors in the food chain: policymakers in different areas, producers, retailers and consumers. When so many different actors have a common responsibility, it is easy for each actor to hold someone else responsible. A new article (with Mirko Ancillotti at CRB as one of the co-authors) discusses a possibility for how this standstill where no one feels accountable can be broken: by empowering consumers to exercise the power they actually have. They are not as passive as we think. On the contrary, through their purchasing decisions, and by communicating their choices in various ways, consumers can put pressure on other consumers as well as other actors in the food chain. They may demand more transparency and better animal husbandry that is not as dependent on antibiotics.

However, antimicrobial resistance is often discussed from a medical perspective, which makes it difficult for consumers to see how their choices in the store could affect the development of resistance. By changing this and empowering consumers to make more aware choices, they could exercise their power as consumers and influence all actors to take joint responsibility for the contribution of food production to antimicrobial resistance, the authors argue. The tendency to shift responsibility to someone else can be broken if consumers demand transparency and responsibility through their purchasing decisions. Policymakers, food producers, retailers and consumers are incentivized to work together to slow the development of antimicrobial resistance.

The article discusses the issue of accountability from a theoretical perspective that can motivate interventions and empirical studies. Read the article here: Antimicrobial resistance and the non-accountability effect on consumers’ behaviour.

Pär Segerdahl

Written by…

Pär Segerdahl, Associate Professor at the Centre for Research Ethics & Bioethics and editor of the Ethics Blog.

Nordvall, A-C., Ancillotti, M., Oljans, E., Nilsson, E. (2025). Antimicrobial resistance and the non-accountability effect on consumers’ behaviour. Social Responsibility Journal. DOI: 10.1108/SRJ-12-2023-0721

This post in Swedish

Approaching future issues

Antimicrobial resistance: bringing the AMR community together

According to the WHO, antibiotic resistance is one of the biggest threats to global health, food security and development. Most of the disease burden is in the global south, but drug resistant infections can affect anyone, in any part of the world. Bacteria are always evolving, and antibiotic resistance is a natural process that develops through mutations. We can slow down the process by using antibiotics responsibly, but to save lives, we urgently need new antibiotics to fight the resistant bacteria that already today threaten our health.

There is a dilemma here: development of new antibiotics is a high-risk business, with very low return of investment, and big pharma is leaving the antibiotics field for precisely this reason. Responsible use of antibiotics means saving new drugs for the most severe cases. There are several initiatives filling the gap this creates. One example is the Innovative Medicines Initiative AMR Accelerator programme, with 9 projects working together to fill the pipeline with new antibiotics, and developing tools and infrastructures that can support antibiotics development.

Antimicrobial resistance (AMR) to antibiotics and other anti-infectives is a community problem. Managing it requires a community coming together to find solutions and work together to develop research infrastructures. For example, assessing the effectiveness of new antibiotics requires standardised high-quality infection models that can become available to projects, companies and research groups that are developing new antibacterial treatments. Recently, the AMR Accelerator COMBINE project announced a collaboration with some of the big players in the field: CARB-X, CAIRD, iiCON and Pharmacology Discovery Services. This kind of collaboration allows key actors to come together and share both expertise and data. The COMBINE project is developing a standardised protocol for an in vivo pneumonia model. It will become available to the scientific community, along with a bank of reference strains of Gram-negative bacteria that are clinically relevant, complete with a framework to bridge the gap between preclinical data and clinical outcomes based on mathematical modelling approaches.

The benefit of a standardised model is to support harmonisation. Ideally, data on how effective new antibiotic candidates are should be the same, regardless of the lab that performed the experiments. The point of the collaboration is to improve quality of the COMBINE pneumonia model. But who are they and what will they do? CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership that supports early-stage antibacterial research and development. They will help validation of the pneumonia model. CAIRD (Center for Anti-Infective Research and Development) is working to advance anti-infective pharmacology. They are providing a benchmark by back-translation of clinical data. iiCON has a mission to accelerate and support the discovery and development of innovative new anti-infectives, diagnostics, and preventative products. They are supporting the mathematical modelling to ensure optimal dose selection. And finally, Pharmacology Discovery Services, a contract research organisation (CRO) working with preclinical antibacterial development, will supply efficacy data.

At the centre of this is the COMBINE project, which has a coordinating role in the AMR Accelerator: a cluster of public-private partnership projects funded by the Innovative Medicines Initiative (IMI). The AMR Accelerator brings together academia, pharma industry, patient organisations, non-profits and small and medium sized companies. The aim is to develop a robust pipeline of antibiotics and standardised tools that can be used by others in this community, to help in the fight against antimicrobial resistance.

In parallel, the effort to slow down antibiotic resistance continues. For example, Uppsala University coordinates the COMBINE project, and in 2016, the University founded the Uppsala Antibiotic Center, a multidisciplinary centre for research, education, innovation and awareness. The centre runs the AMR Studio podcast, showcasing some of the multidisciplinary research on antimicrobial resistance around the world. The University is also coordinating the ENABLE-2 antibacterial drug discovery platform funded by the Swedish Research Council, with an open call to support programmes in the early stages of discovery and development of new antibiotics.

Our own efforts at the Centre for Research Ethics & Bioethics are more focused on how we as individuals can help slow down the development of antibiotic resistance, and how we can assess the impact of how you frame antibiotic treatments when you ask patients about their preferences

Josepine Fernow

Written by…

Josepine Fernow, science communications project manager and coordinator at the Centre for Research Ethics & Bioethics, develops communications strategy for European research projects

Do you want to know more?

EurekAlert! News release: Collaboration to improve the quality of in vivo antibiotics testing, 14 November 2023 https://www.eurekalert.org/news-releases/1007971.

Ancillotti M, Nihlén Fahlquist J, Eriksson S, Individual moral responsibility for antibiotic resistance, Bioethics, 2022;36(1):3-9. https://doi.org/10.1111/bioe.12958

Smith IP, Ancillotti M, de Bekker-Grob EW, Veldwijk J. Does It Matter How You Ask? Assessing the Impact of Failure or Effectiveness Framing on Preferences for Antibiotic Treatments in a Discrete Choice Experiment. Patient Prefer Adherence. 2022;16:2921-2936. https://doi.org/10.2147/PPA.S365624

A shorter version of this post in Swedish

Approaching future issues